Indivior: Difference between revisions
demoted |
No edit summary |
||
| Line 25: | Line 25: | ||
The company was established as the [[Buprenorphine]] division of [[Reckitt Benckiser]] in 1994.<ref name=investors>{{cite web|url=http://www.investorschronicle.co.uk/2015/02/02/shares/news-and-analysis/indivior-faces-generic-challenge-uoAMCw7Vo28Wy1N4K731OP/article.html|title=Indivior faces generic challenge|publisher=Investors Chronicle|date=2 February 2015|accessdate=22 March 2015}}</ref> In December 2014, Reckitt Benckiser spun off its specialty pharmaceuticals business into a separate company named Indivior.<ref>{{cite web|url=https://www.rb.com/rb-complete-demerger-of-indivior|title=RB complete demerger of Indivior - RB|work=RB|date=23 December 2014|accessdate=21 March 2015|deadurl=yes|archiveurl=https://web.archive.org/web/20150329132943/http://www.rb.com/rb-complete-demerger-of-indivior|archivedate=29 March 2015|df=dmy-all}}</ref> By February 2015 the company was capitalised at £2.3 billion on the [[London Stock Exchange]].<ref>{{cite web|url=http://www.fool.co.uk/investing/2015/02/11/is-indivior-plc-the-perfect-partner-for-astrazeneca-plc-in-your-portfolio/|title=Is Indivior PLC The Perfect Partner For AstraZeneca plc In Your Portfolio?|accessdate=22 March 2015}}</ref> |
The company was established as the [[Buprenorphine]] division of [[Reckitt Benckiser]] in 1994.<ref name=investors>{{cite web|url=http://www.investorschronicle.co.uk/2015/02/02/shares/news-and-analysis/indivior-faces-generic-challenge-uoAMCw7Vo28Wy1N4K731OP/article.html|title=Indivior faces generic challenge|publisher=Investors Chronicle|date=2 February 2015|accessdate=22 March 2015}}</ref> In December 2014, Reckitt Benckiser spun off its specialty pharmaceuticals business into a separate company named Indivior.<ref>{{cite web|url=https://www.rb.com/rb-complete-demerger-of-indivior|title=RB complete demerger of Indivior - RB|work=RB|date=23 December 2014|accessdate=21 March 2015|deadurl=yes|archiveurl=https://web.archive.org/web/20150329132943/http://www.rb.com/rb-complete-demerger-of-indivior|archivedate=29 March 2015|df=dmy-all}}</ref> By February 2015 the company was capitalised at £2.3 billion on the [[London Stock Exchange]].<ref>{{cite web|url=http://www.fool.co.uk/investing/2015/02/11/is-indivior-plc-the-perfect-partner-for-astrazeneca-plc-in-your-portfolio/|title=Is Indivior PLC The Perfect Partner For AstraZeneca plc In Your Portfolio?|accessdate=22 March 2015}}</ref> |
||
In 2019, Indivior was indicted over claims that it had made false marketing claims about the effectiveness of its drug, Suboxone, and had concocted a scheme to direct patients towards doctors who were likely to prescribe Suboxone. |
In 2019, Indivior was indicted over claims that it had made false marketing claims about the effectiveness of its drug, Suboxone, and had concocted a scheme to direct patients towards doctors who were likely to prescribe Suboxone. Reckitt Benckiser has settled with [[United States Department of Justice|justice department]] to pay $1.4 billion to resolve U.S. federal investigation into sales and marketing of opioid addiction treatment. |
||
==Operations== |
==Operations== |
||
Revision as of 09:16, 11 July 2019
 | |
| Company type | Public company |
|---|---|
| LSE: INDV | |
| Industry | pharmaceuticals |
| Founded | 1994 |
| Headquarters | Richmond, Virginia |
Key people | Howard Pien, Chairman Shaun Thaxter, CEO |
| Products | Subutex/Subuxone |
| Revenue | $1,005 million (2018)[1] |
| $292 million (2018)[1] | |
| $275 million (2018)[1] | |
Number of employees | 915 (2018)[1] |
| Website | www.indivior.com/ |
Indivior is a specialty pharmaceuticals business. It is listed on the London Stock Exchange.
History
The company was established as the Buprenorphine division of Reckitt Benckiser in 1994.[2] In December 2014, Reckitt Benckiser spun off its specialty pharmaceuticals business into a separate company named Indivior.[3] By February 2015 the company was capitalised at £2.3 billion on the London Stock Exchange.[4]
In 2019, Indivior was indicted over claims that it had made false marketing claims about the effectiveness of its drug, Suboxone, and had concocted a scheme to direct patients towards doctors who were likely to prescribe Suboxone. Reckitt Benckiser has settled with justice department to pay $1.4 billion to resolve U.S. federal investigation into sales and marketing of opioid addiction treatment.
Operations
The company's main products are Subutex and its Naloxone-combined preparation Suboxone, both substitution products for opioid addiction.[2] Other products include remedies for cocaine and opioid analgesic overdose and treatment for alcohol dependence: the company claims this to be the largest pipeline of addiction drugs in the world.[5]
References
- ^ a b c d "Annual Report 2018" (PDF). Indivior. Retrieved 18 March 2019.
- ^ a b "Indivior faces generic challenge". Investors Chronicle. 2 February 2015. Retrieved 22 March 2015.
- ^ "RB complete demerger of Indivior - RB". RB. 23 December 2014. Archived from the original on 29 March 2015. Retrieved 21 March 2015.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help) - ^ "Is Indivior PLC The Perfect Partner For AstraZeneca plc In Your Portfolio?". Retrieved 22 March 2015.
- ^ "RB spin-out Indivior says addiction pipeline will deliver". Pharmaphorum. 21 November 2014. Retrieved 22 March 2015.